Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
145.10
+2.57 (1.80%)
At close: Sep 5, 2025, 4:00 PM
145.00
-0.10 (-0.07%)
After-hours: Sep 5, 2025, 7:50 PM EDT
Insmed Employees
Insmed had 1,271 employees as of December 31, 2024. The number of employees increased by 359 or 39.36% compared to the previous year.
Employees
1,271
Change (1Y)
359
Growth (1Y)
39.36%
Revenue / Employee
$313,222
Profits / Employee
-$813,801
Market Cap
30.67B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 1,271 | 359 | 39.36% |
Dec 31, 2023 | 912 | 176 | 23.91% |
Dec 31, 2022 | 736 | 123 | 20.07% |
Dec 31, 2021 | 613 | 92 | 17.66% |
Dec 31, 2020 | 521 | 86 | 19.77% |
Dec 31, 2019 | 435 | 62 | 16.62% |
Dec 31, 2018 | 373 | 159 | 74.30% |
Dec 31, 2017 | 214 | 53 | 32.92% |
Dec 31, 2016 | 161 | 36 | 28.80% |
Dec 31, 2015 | 125 | 36 | 40.45% |
Dec 31, 2014 | 89 | 28 | 45.90% |
Dec 31, 2013 | 61 | 20 | 48.78% |
Dec 31, 2012 | 41 | -1 | -2.38% |
Dec 31, 2011 | 42 | 2 | 5.00% |
Dec 31, 2010 | 40 | 25 | 166.67% |
Dec 31, 2009 | 15 | -82 | -84.54% |
Dec 31, 2008 | 97 | 3 | 3.19% |
Dec 31, 2007 | 94 | -63 | -40.13% |
Dec 31, 2006 | 157 | 72 | 84.71% |
Dec 31, 2005 | 85 | 30 | 54.55% |
Dec 31, 2004 | 55 | 35 | 175.00% |
Dec 31, 2003 | 20 | -3 | -13.04% |
Dec 31, 2002 | 23 | -37 | -61.67% |
Dec 31, 2001 | 60 | 20 | 50.00% |
Dec 31, 2000 | 40 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
INSM News
- 1 day ago - Insmed Incorporated (INSM) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 Transcript - Seeking Alpha
- 1 day ago - Insmed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PRNewsWire
- 16 days ago - Insmed To Present at September Investor Conferences - PRNewsWire
- 17 days ago - Lung Disease-Focused Insmed 'Must-Own' Name For Investors - Benzinga
- 25 days ago - FDA Approves Insmed's Drug As First Treatment For Type Of Chronic Lung Disease - Benzinga
- 25 days ago - US FDA approves Insmed's lung disease drug - Reuters
- 25 days ago - FDA Approves BRINSUPRI™ (brensocatib) as the First and Only Treatment for Non-Cystic Fibrosis Bronchiectasis, a Serious, Chronic Lung Disease - PRNewsWire
- 4 weeks ago - Insmed Incorporated (INSM) Q2 2025 Earnings Call Transcript - Seeking Alpha